Literature DB >> 2730380

Amantadine treatment of fatigue associated with multiple sclerosis.

R A Cohen1, M Fisher.   

Abstract

Fatigue is a common symptom of multiple sclerosis (MS) that is without an effective treatment. A double-blind, controlled study of fatigue treatment was conducted to evaluate the efficacy of amantadine hydrochloride in treating MS-associated fatigue. Since fatigue cannot be characterized by a single symptom or behavior, a variety of neuropsychological, behavioral, and self-report measures were used to monitor changes across different systems. According to patients' daily diary ratings, amantadine produced small but statistically significant improvements in fatigue across four of seven dimensions (overall energy level, concentration, problem solving, and sense of well-being). In addition, patients with MS who were taking amantadine performed slightly better on the Stroop Interference Test, an attentional measure of freedom from distracting information. Although retrospective reports by patients with MS did not confirm the degree of improvement recorded on a daily basis, the study's results suggested that amantadine may offer modest benefits in alleviating the day-to-day subjective experience of fatigue.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2730380     DOI: 10.1001/archneur.1989.00520420096030

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  31 in total

Review 1.  Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment.

Authors:  Tiffany J Braley; Ronald D Chervin
Journal:  Sleep       Date:  2010-08       Impact factor: 5.849

Review 2.  Amantadine for fatigue in multiple sclerosis.

Authors:  E Pucci; P Branãs; R D'Amico; G Giuliani; A Solari; C Taus
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

3.  Elements of attention in HIV-infected adults: evaluation of an existing model.

Authors:  Andrew J Levine; David J Hardy; Terry R Barclay; Matthew J Reinhard; Michael M Cole; Charles H Hinkin
Journal:  J Clin Exp Neuropsychol       Date:  2007-03-12       Impact factor: 2.475

Review 4.  Neurology.

Authors:  A N Gale; J M Gibbs; A H Schapira; P K Thomas
Journal:  Postgrad Med J       Date:  1991-06       Impact factor: 2.401

5.  Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial.

Authors:  M P J Garssen; P I M Schmitz; I S J Merkies; B C Jacobs; F G A van der Meché; P A van Doorn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-01       Impact factor: 10.154

Review 6.  Fatigue in multiple sclerosis: a rational approach to evaluation and treatment.

Authors:  Jay H Rosenberg; Renata Shafor
Journal:  Curr Neurol Neurosci Rep       Date:  2005-03       Impact factor: 5.081

Review 7.  Fatigue in neuromuscular disorders: focus on Guillain-Barré syndrome and Pompe disease.

Authors:  J M de Vries; M L C Hagemans; J B J Bussmann; A T van der Ploeg; P A van Doorn
Journal:  Cell Mol Life Sci       Date:  2010-03       Impact factor: 9.261

Review 8.  [Therapy of fatigue in multiple sclerosis : A treatment algorithm].

Authors:  C Veauthier; F Paul
Journal:  Nervenarzt       Date:  2016-12       Impact factor: 1.214

Review 9.  Pediatric multiple sclerosis.

Authors:  Brenda L Banwell
Journal:  Curr Neurol Neurosci Rep       Date:  2004-05       Impact factor: 5.081

Review 10.  Choosing drug therapy for multiple sclerosis. An update.

Authors:  B W van Oosten; L Truyen; F Barkhof; C H Polman
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.